image credit: Unsplash

PDS Biotechnology and Farmacore Biotechnology

PDS Biotechnology said June 17 that it signed an agreement with Farmacore Biotechnology to co-develop Versamune®-CoV-2FC. PDS and Farmacore agreed to accelerate development of the vaccine candidate into Phase 1 clinical testing in Brazil, with initial financial support to be provided by the Brazilian Ministry of Science, Technology, Innovation and Communication (MCTIC). The companies are expanding upon an earlier-announced R&D collaboration designed to develop a Versamune®-based vaccine for tuberculosis.

PDS and Farmacore said they plan to use multiple R&D sites in the U.S. and Brazil for preclinical and clinical development of Versamune-CoV-2FC.

Read More on Genetic Engineering and Biotechnology News